Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase

  • Bioorg Med Chem Lett. 2013 Jun 15;23(12):3584-8. doi: 10.1016/j.bmcl.2013.04.019.
Reema K Thalji  1 ,  Jeff J McAtee ,  Svetlana Belyanskaya ,  Martin Brandt ,  Gregory D Brown ,  Melissa H Costell ,  Yun Ding ,  Jason W Dodson ,  Steve H Eisennagel ,  Rusty E Fries ,  Jeffrey W Gross ,  Mark R Harpel ,  Dennis A Holt ,  David I Israel ,  Larry J Jolivette ,  Daniel Krosky ,  Hu Li ,  Quinn Lu ,  Tracy Mandichak ,  Theresa Roethke ,  Christine G Schnackenberg ,  Benjamin Schwartz ,  Lisa M Shewchuk ,  Wensheng Xie ,  David J Behm ,  Stephen A Douglas ,  Ami L Shaw ,  Joseph P Marino Jr
Affiliations
  • 1. Department of Chemistry, Heart Failure Disease Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area Unit, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406, USA.
PMID: 23664879 DOI: 10.1016/j.bmcl.2013.04.019
Abstract

1-(1,3,5-Triazin-yl)piperidine-4-carboxamide inhibitors of soluble Epoxide Hydrolase were identified from high through-put screening using encoded library technology. The triazine heterocycle proved to be a critical functional group, essential for high potency and P450 selectivity. Phenyl group substitution was important for reducing clearance, and establishing good oral exposure. Based on this lead optimization work, 1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-{[[4-bromo-2-(trifluoromethoxy)]-phenyl]methyl}-4-piperidinecarboxamide (27) was identified as a useful tool compound for in vivo investigation. Robust effects on a serum biomarker, 9, 10-epoxyoctadec-12(Z)-enoic acid (the epoxide derived from linoleic acid) were observed, which provided evidence of robust in vivo target engagement and the suitability of 27 as a tool compound for study in various disease models.

Products